LAEKNA-B(02105),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02105 LAEKNA-B

Not Yet Opened 11-12 16:08:06

6.875

+0.275

+4.17%

High7.060	Low6.500	Vol1.72M
Open6.575	D1 Closing6.600	Amplitude8.48%
Mkt Cap3.11B	Tradable Cap3.11B	Total Shares452.00M
T/O11.82M	T/O Rate0.38%	Tradable Shares452.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"LAEKNA-B","latestPrice":6.875,"timestamp":1794470886003,"preClose":6.6,"halted":0,"volume":1724500,"delay":0,"changeRate":0.04166666666666672,"floatShares":451999999,"shares":451999999,"eps":-0.59,"marketStatus":"Not Yet Opened","change":0.275,"latestTime":"11-12 16:08:06","open":6.575,"high":7.06,"low":6.5,"amount":11815123,"amplitude":0.084848,"askPrice":6.9,"askSize":6000,"bidPrice":6.87,"bidSize":155500,"shortable":3,"etf":0,"ttmEps":-0.26,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1794533400000},"marketStatusCode":0,"adr":0,"listingDate":1687968000000,"exchange":"SEHK","adjPreClose":6.6,"openAndCloseTimeList":[[1794447000000,1794456000000],[1794459600000,1794470400000]],"volumeRatio":1.3760772421060878,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02105/tweets","defaultTab":"tweets","newsList":[{"id":"2682530524","title":"Laekna's Oral Obesity Drug Lae124 Reduces Body Weight in Rat Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2682530524","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682530524?lang=en_us&edition=fundamental","pubTime":"2026-11-12 12:02","pubTimestamp":1794456139,"startTime":"0","endTime":"0","summary":"Laekna's Oral Obesity Drug LAE124 Reduces Body Weight in Rat StudiesLaekna will present animal-study results for oral obesity drug LAE124 at Obesity Week on Nov. 15, 2026, in Washington, D.C.LAE124 re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nNDL9Nd0nD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682853054","title":"Obesity Week 2026 | Laekna Announces Poster Presentation on Lae124, an Internally Discovered Oral Small-Molecule Amylin Receptor Agonist","url":"https://stock-news.laohu8.com/highlight/detail?id=2682853054","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682853054?lang=en_us&edition=fundamental","pubTime":"2026-11-12 12:01","pubTimestamp":1794456100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nTUA6WRTC3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198564171","title":"Next Big Trend in Metabolic Drugs: Laekna-B (02105) Builds Full Coverage Across the Field","url":"https://stock-news.laohu8.com/highlight/detail?id=1198564171","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198564171?lang=en_us&edition=fundamental","pubTime":"2026-11-10 08:42","pubTimestamp":1794271342,"startTime":"0","endTime":"0","summary":"In the global metabolic drug field, as clinical research continues to release positive signals, the therapeutic potential of activin type II receptors (ActRII) is attracting growing attention from...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182757981","title":"Laekna-B (02105): Phase I SAD Study of LAE103 in Overweight or Obese Subjects Successfully Completed","url":"https://stock-news.laohu8.com/highlight/detail?id=1182757981","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182757981?lang=en_us&edition=fundamental","pubTime":"2026-11-09 08:28","pubTimestamp":1794184091,"startTime":"0","endTime":"0","summary":"Laekna-B (02105) has announced that the company has successfully completed a Phase I single ascending dose (SAD) study of LAE103 (an ActRIIB monoclonal antibody) in overweight or obese subjects in...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682978824","title":"Laekna Completes Phase I Study of Lae103 in Overweight or Obese Participants","url":"https://stock-news.laohu8.com/highlight/detail?id=2682978824","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682978824?lang=en_us&edition=fundamental","pubTime":"2026-11-09 08:12","pubTimestamp":1794183170,"startTime":"0","endTime":"0","summary":"Laekna completes Phase I study of LAE103 in overweight or obese participantsLaekna disclosed completed Phase I trial results for LAE103 in overweight or obese participants in Australia on November 9, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261109:nNDL35vJ0r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125792263","title":"Laekna-B Maintains 452.06 Million Issued Shares in October, Affirms Public Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1125792263","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125792263?lang=en_us&edition=fundamental","pubTime":"2026-11-05 16:42","pubTimestamp":1793868172,"startTime":"0","endTime":"0","summary":"Laekna, Inc. (Laekna-B) reported no changes in its share capital structure for the month ended 31 October 2026, according to its latest Monthly Return filed with Hong Kong Exchanges and Clearing...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101135616","title":"LAEKNA-B (02105) Surges Over 5% After Completing 24-Week Low-Dose Monotherapy Study Treatment Group for LAE102","url":"https://stock-news.laohu8.com/highlight/detail?id=1101135616","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101135616?lang=en_us&edition=fundamental","pubTime":"2026-10-14 11:26","pubTimestamp":1791948373,"startTime":"0","endTime":"0","summary":"According to a report, LAEKNA-B (02105) rose more than 5%, reaching 4.46% as of press time at HK$6.795, with a turnover of HK$2.3566 million.On the news front, on October 13, LAEKNA-B announced that...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1161","KCAI","BK4585","VXUS","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675233687","title":"Laekna's Obesity Drug Shows Promise in Early Stage Testing; Shares Fall 11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675233687","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675233687?lang=en_us&edition=fundamental","pubTime":"2026-10-13 14:56","pubTimestamp":1791874615,"startTime":"0","endTime":"0","summary":"Laekna (HKG:2105) said early-stage low-dose testing of its obesity treatment candidate LAE102 was well tolerated and led to reductions in fat mass among participants, according to a Tuesday filing to ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186118206","title":"Laekna-B (02105) Rises Over 21% in Early Trading as First Patient Enrolled in Phase I Trial of LAE118","url":"https://stock-news.laohu8.com/highlight/detail?id=1186118206","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186118206?lang=en_us&edition=fundamental","pubTime":"2026-09-30 11:32","pubTimestamp":1790739141,"startTime":"0","endTime":"0","summary":"Shares of Laekna-B (02105) climbed more than 21% in early trading. As of press time, the stock is up 18.33% at HK$7.585, with turnover of HK$32.8341 million.On the news front, Laekna recently...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4588","KCAI","02105","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133785440","title":"Laekna Reports 1H26 Turnaround on Licensing Income; Loss Narrows to RMB 2.55 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1133785440","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133785440?lang=en_us&edition=fundamental","pubTime":"2026-09-18 23:06","pubTimestamp":1789743975,"startTime":"0","endTime":"0","summary":"Laekna, Inc. (LAEKNA-B) released its unaudited 2026 interim results, highlighting a sharp improvement in profitability driven by upfront and milestone payments from recent out-licensing deals....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Laekna Reports 1H26 Turnaround on Licensing Income; Loss Narrows to RMB 2.55 Million","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182468251","title":"Laekna Issues 2.73 Million New Shares for RSU Vesting, Lifting Share Count by 0.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=1182468251","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182468251?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:23","pubTimestamp":1788870217,"startTime":"0","endTime":"0","summary":"Laekna, Inc. disclosed that on 08 September 2026 it issued a total of 2.73 million ordinary shares to satisfy the vesting of restricted stock units (RSUs) granted under its 2024 Share Award Scheme. •...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167154533","title":"LAEKNA-B Issues 273,000 Shares to Settle RSU Vesting Under 2024 Equity Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1167154533","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167154533?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:20","pubTimestamp":1788870037,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) has announced that on September 8, 2026, the company issued a total of 273,000 ordinary shares to satisfy the vesting of restricted share units (RSUs) granted under its 2024 share...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320280","title":"Laekna Files HKEX Next-Day Disclosure, Issues 2.73 Million New Shares to Lift Share Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320280","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320280?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:15","pubTimestamp":1788869712,"startTime":"0","endTime":"0","summary":"Laekna files HKEX next-day disclosure, issues 2.73 million new shares to lift share capitalLaekna filed a next-day disclosure return on Sept. 8, 2026, reporting 2,730,000 new ordinary shares issued fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL21glBL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121016709","title":"Laekna Maintains 449.33 Million Shares Outstanding in August 2026, Confirms Adequate Public Float","url":"https://stock-news.laohu8.com/highlight/detail?id=1121016709","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121016709?lang=en_us&edition=fundamental","pubTime":"2026-09-04 17:47","pubTimestamp":1788515267,"startTime":"0","endTime":"0","summary":"Laekna, Inc. (Laekna) reported no changes to its capital structure for the month ended 31 August 2026, according to the company’s monthly return filed with Hong Kong Exchanges and Clearing Limited on...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157665370","title":"HK Stocks in Focus: LAEKNA-B (02105) Jumps Over 9% in Early Trading After First Patient Dosed in Phase I Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1157665370","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157665370?lang=en_us&edition=fundamental","pubTime":"2026-09-01 09:52","pubTimestamp":1788227576,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) saw its share price surge more than 9% in early trading on Thursday, with the stock last changing hands at HK$7.005, marking a gain of 9.37%. Trading volume has reached approximately...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCAI","BK1161","BK4588","VXUS","02105","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163609757","title":"LAEKNA-B Initiates First-Patient Dosing in Phase I Trial of LAE118, a Novel Pan-Mutant-Selective PI3Kα Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=1163609757","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163609757?lang=en_us&edition=fundamental","pubTime":"2026-09-01 08:22","pubTimestamp":1788222165,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) has announced that it has commenced subject recruitment for its Phase I clinical study of LAE118, designed to treat advanced solid tumors, in China. The company confirmed that...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664899538","title":"Laekna Enrolls First Patient in China Phase I Trial of Cancer Drug Candidate Lae118","url":"https://stock-news.laohu8.com/highlight/detail?id=2664899538","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664899538?lang=en_us&edition=fundamental","pubTime":"2026-09-01 08:11","pubTimestamp":1788221498,"startTime":"0","endTime":"0","summary":"Laekna enrolls first patient in China Phase I trial of cancer drug candidate LAE118Laekna began a Phase I study of LAE118 in China for advanced solid tumors, enrolling the first participant.No clinica","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL5vvH85:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662989032","title":"Analysts Just Made A Significant Upgrade To Their Laekna, Inc. (HKG:2105) Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2662989032","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662989032?lang=en_us&edition=fundamental","pubTime":"2026-08-28 06:11","pubTimestamp":1787868676,"startTime":"0","endTime":"0","summary":"Laekna, Inc. ( HKG:2105 ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2105/laekna-shares/news/analysts-just-made-a-significant-upgrade-to-their-laekna-inc","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2105/laekna-shares/news/analysts-just-made-a-significant-upgrade-to-their-laekna-inc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174075405","title":"LAEKNA-B Announces Interim Results with Other Income Climbing 30.41% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1174075405","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174075405?lang=en_us&edition=fundamental","pubTime":"2026-08-26 08:50","pubTimestamp":1787705422,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) has unveiled its interim results for the six-month period ending June 30, 2026, showcasing a robust increase in other income alongside a significant narrowing of its net loss.The...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180311859","title":"LAEKNA-B (02105) Posts Interim Results: Other Income Up 30.41% to RMB 25.962 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1180311859","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180311859?lang=en_us&edition=fundamental","pubTime":"2026-08-25 23:06","pubTimestamp":1787670381,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) has disclosed its interim results for the six months ended June 30, 2026. The group recorded other income of RMB 25.962 million, representing a year-on-year increase of 30.41%....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.laekna.com","stockEarnings":[{"period":"1week","weight":0.0504},{"period":"1month","weight":0.0569},{"period":"3month","weight":-0.0179},{"period":"6month","weight":-0.5367},{"period":"1year","weight":-0.4124},{"period":"ytd","weight":-0.4934}],"compareEarnings":[{"period":"1week","weight":-0.0318},{"period":"1month","weight":-0.0138},{"period":"3month","weight":-0.0441},{"period":"6month","weight":-0.0753},{"period":"1year","weight":-0.1082},{"period":"ytd","weight":-0.0633}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer, liver diseases and obesity. The Company is still in the research and development stage. The Company's pipeline products include Afuresertib (LAE002), LAE001, LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, LAE102, LAE103, LAE104, LAE105, LAE106, LAE120, LAE123, and others. The Afuresertib is an adenosine triphosphate (ATP) competitive AKT inhibitor. The LAE001 is an androgen synthesis inhibitor that can inhibit CYP17A1 and CYP11B2 at the same time. The Company mainly conducts business in the Chinese, America, European, Korean, and other markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.264392},{"month":2,"riseRate":0.666667,"avgChangeRate":0.234103},{"month":3,"riseRate":0.666667,"avgChangeRate":0.090739},{"month":4,"riseRate":0.333333,"avgChangeRate":0.001974},{"month":5,"riseRate":0.666667,"avgChangeRate":0.062052},{"month":6,"riseRate":0,"avgChangeRate":-0.226423},{"month":7,"riseRate":0.25,"avgChangeRate":-0.072516},{"month":8,"riseRate":0.75,"avgChangeRate":0.06659},{"month":9,"riseRate":0.75,"avgChangeRate":0.102989},{"month":10,"riseRate":0.5,"avgChangeRate":0.000639},{"month":11,"riseRate":1,"avgChangeRate":0.357832},{"month":12,"riseRate":0,"avgChangeRate":-0.176326}],"exchange":"SEHK","name":"LAEKNA-B","nameEN":"LAEKNA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LAEKNA-B(02105),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LAEKNA-B(02105) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LAEKNA-B,02105,LAEKNA-B股票,LAEKNA-B股票老虎,LAEKNA-B股票老虎国际,LAEKNA-B行情,LAEKNA-B股票行情,LAEKNA-B股价,LAEKNA-B股市,LAEKNA-B股票价格,LAEKNA-B股票交易,LAEKNA-B股票购买,LAEKNA-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LAEKNA-B(02105),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LAEKNA-B(02105) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}